AI summary by TwinMind

The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug | WSJ

The Wall Street Journal

6m 10s

Alzheimer's Disease Overview

  • Time lapse shows normal brain vs Alzheimer's brain over 6 years
  • Disease kills 120,000+ people annually in US
  • Researchers spent 3+ decades trying to cure
  • Current drugs only alleviate symptoms, don't slow disease progression
  • Biogen's Aduhelm (aducanumab) aims to be first drug to slow progression

Alzheimer's Disease Mechanism

  • Attacks neurons controlling movement, senses, memory, thinking
  • Communication between neurons interrupted, cells die
  • Two key biomarkers: amyloid plaques and tau tangles
  • Normal proteins (amyloid precursor protein, tau protein) needed for brain function
  • In Alzheimer's: proteins modified, aggregate/clump together
  • Beta-amyloid plaques accumulate throughout brain, block cell communication
  • Tau tangles build up inside neurons, block nutrient pathways
  • Plaques and tangles kill brain cells permanently

Aduhelm Drug Mechanism

  • Generic name: aducanumab
  • Targets amyloid plaques using monoclonal antibodies
  • Antibodies designed in lab, modeled on natural antibodies from Alzheimer's-resistant people
  • Process:
    • Antibodies injected, travel to brain via bloodstream
    • Latch onto plaques
    • Attract microglia (natural scavenging cells)
    • Microglia digest plaque material
    • Amyloid cleared through blood vessels
  • Theory: removing plaques slows/stops accumulation, delays brain cell death

Clinical Trial Controversy (Since 2019)

  • Biogen ran two large Phase 3 trials
  • Shut down prematurely - thought trials wouldn't work
  • Later pooled analysis showed different results when examined separately
  • Both trials: effective at reducing brain plaque
  • Only one trial: showed effect on patient decline (22% slowing of symptom progression)
  • Joseph Walker (biotech reporter) covered controversial development

FDA Approval Decision

  • Granted accelerated approval despite incomplete evidence
  • Drug not fully proven but showed promising results
  • Can be prescribed while additional study conducted
  • FDA cited urgent need for treatments
  • Many doctors question insufficient evidence of benefits/safety

Safety Concerns

  • Side effects from amyloid removal:
    • Brain swelling
    • Small brain bleeds
  • Contested theory: removing amyloid alone will slow Alzheimer's
  • Some consider approval premature based on unproven amyloid hypothesis

Cost and Access Issues

  • Initial price: $56,000 per year for average person
  • Sticker shock caused insurer coverage limitations
  • Price cut in half December 2021
  • Many health insurers and doctors reluctant to cover/prescribe
  • Creates uncertainty around drug adoption

Future Outlook

  • Other companies testing amyloid-targeting treatments
  • Dr. Paul Aisen (Biogen consultant): most encouraging results in 30 years of research
  • Work stimulated and excited the field despite controversy
  • Currently approved only for early-stage patients
  • Biogen conducting confirmatory trial
  • Final results likely years away

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome